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Background: Epithelial ovarian cancer is characterized by multiple genomic alterations; most are passenger
alterations which do not confer tumor growth. Like many cancers, it is a heterogeneous disease and can be broadly
categorized into 4 main histotypes of clear cell, endometrioid, mucinous, and serous. To date, histotype-specific
copy number alterations have been difficult to elucidate. The difficulty lies in having sufficient sample size in each
histotype for statistical analyses.
Methods: To dissect the heterogeneity of ovarian cancer and identify histotype-specific alterations, we used an
in silico hypothesis-driven approach on multiple datasets of epithelial ovarian cancer.
Results: In concordance with previous studies on global copy number alterations landscape, the study showed
similar alterations. However, when the landscape was de-convoluted into histotypes, distinct alterations were
observed. We report here significant histotype-specific copy number alterations in ovarian cancer and showed that
there is genomic diversity amongst the histotypes. 76 cancer genes were found to be significantly altered with
several as potential copy number drivers, including ERBB2 in mucinous, and TPM3 in endometrioid histotypes.
ERBB2 was found to have preferential alterations, where it was amplified in mucinous (28.6%) but deleted in serous
tumors (15.1%). Validation of ERBB2 expression showed significant correlation with microarray data (p=0.007). There
also appeared to be reciprocal relationship between KRAS mutation and copy number alterations. In mucinous
tumors where KRAS mutation is common, the gene was not significantly altered. However, KRAS was significantly
amplified in serous tumors where mutations are rare in high grade tumors.
Conclusions: The study demonstrates that the copy number landscape is specific to the histotypes and
identification of these alterations can pave the way for targeted drug therapy specific to the histotypes.
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Ovarian cancer is often dubbed a ‘silent’ killer because of
its non-specific symptoms and late clinical onset which
contribute to overall poor prognosis. There has been a
steady increase in incidence over the last three decades
with 204,000 new cases diagnosed each year globally [1].
It ranked fifth in mortality among cancers in women
and has the highest case-fatality rate in gynecological* Correspondence: liang.goh@duke-nus.edu.sg
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reproduction in any medium, provided the orcancers [2]. The 5-year survival rate for women with
advanced disease remains at 29% with estimated 125,000
deaths annually [1,3].
About 90% ovarian cancers are epithelial ovarian cancer
(EOC) [4], histologically subtyped as serous, mucinous,
endometrioid, or clear cell. Further subtyping include the
borderline cases, such as mucinous or serous borderline,
often presented as stable diseases with more favorable out-
come compared to the non-borderline subtypes. It is now
recognized that epithelial ovarian cancer is a spectrum of
diseases with varied genetic mutations among histotypes
[5]. Genetically, mutations differ between the grades of the
disease. Low-grade serous carcinoma have high frequency
of KRAS and BRAF mutations but few p53 mutationsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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frequency of these mutations [6,7]. Mucinous histotype
has KRAS mutations [8] and endometrioid has PTEN
mutations [9]. Despite the molecular heterogeneity, the
treatment standard remains as taxane/platinum-based
chemotherapy for all histotypes.
Genomic alterations such as copy number alterations
(CNA) have been known to harbor drivers in carcino-
genesis. Driver genes are genes that confer growth ad-
vantage on the cancer cells [10]. Several known copy
number alteration drivers in cancers include receptor
tyrosine kinases such as EGFR, FGFR, and ERBB2, which
are targets for drugs therapy [11]. Successful incorpor-
ation of genomics alterations studies in cancer treatment
has been evident in breast, leukemia, and lung cancers,
where targeted therapies are part of the standard treat-
ment protocols [12-14]. For example, Trastuzumab, a
targeted therapy that can significantly reduce risk of dis-
ease recurrence and improve overall survival, is now
standard of care for early-stage patients with Her2-
positive breast cancer [14]. To date, targeted drug ther-
apy has not been successfully incorporated in EOC.
One of the challenges in elucidating copy number
alterations in EOC is the disproportional prevalence of
histotype. Serous is the most prevalent (70-85%), fol-
lowed by endometrioid (5-10%), clear cell (5-10%), and
mucinous (~5%). The lower prevalent diseases tend to
suffer from small sample size for statistical analyses to
identify copy number alterations. To elucidate CNA in
each histotype, we combined data from multiple studies
with similar platforms to identify copy number altera-
tions that are specific to the histotypes. The motivation
is to identify high confidence histotype-specific altera-
tions that may otherwise be obscured due to dispropor-
tionate prevalence of the histotypes.
Results
Two major results are presented here; the histotype-
specific copy number alterations for EOC and the identi-
fication of potential driver genes. Three datasets with
corresponding gene expression and copy number profil-
ing on similar platforms were used for this study. A
hypothesis-driven approach using stringent false discov-
ery rate (FDR) filtering was used to identify potential
copy number driver genes (Methods). The genes were
compared with other studies as well as cancer genes
reported in literature. In addition, we also validated the
expression of ERBB2, a driver gene, via quantitative real-
time PCR (qPCR).
Distinct copy number alterations in EOC histotypes
Figure 1a shows the global frequency of copy number
aberrations for EOC across the genome for the merged
dataset. In concordance with other reports, the fourcommonly reported chromosomes of 3q, 8, 17p, and 20q
showed broad copy number alterations in EOC [15-17].
When this was de-convoluted into histotypes (Figure 1b,
shown in 4 tracks for clear cell, endometrioid, mucinous,
and serous), distinct differences were observed. It is evi-
dent that the general frequency for EOC was mirrored
in serous tumors, not surprising since it has the largest
sample size. In the four most commonly reported altered
regions, 3q, 8, and 20q amplifications were observed in
serous, clear cell, endometrioid but not mucinous tumors.
Endometrioid and serous tend to harbor more copy num-
ber alterations, with more broad regions of alterations in-
volving the p- or q-arm. The genomics landscape for clear
cell and mucinous tumors appeared different from the
other histotypes, with lesser broad regions of alterations
and in lower frequency.
To assess the significance of copy number altered
regions, we used a 2-pronged approach using merged
and individual datasets (Additional file 1: Figure S1).
Figure 2 shows significant copy number altered regions
(see Methods) in the histotypes. Broad 3p amplification
and 8p deletion were observed in serous tumors; 8q
amplifications in clear cell and serous tumors; 17p de-
letions in mucinous and serous tumors; and chr20 amplifi-
cations in serous tumors. The nature of the alterations
also differs, e.g. focal versus broad alterations. For example
in 3q, serous tumors showed broader amplifications in the
region of 3q13.31-29 while focal amplification was
observed for clear cell tumors at 3q26.2-26.32. This is
interesting as it has been reported that overlapping broad
and focal aberrations can have distinct functional conse-
quences [18]. In other chromosomes, alterations were spe-
cific to histotypes as well; such as 9p21 focal deletions in
mucinous histotype, reportedly harboring homozygous
deletions in EOC [19-22]. There are regions that displayed
opposite trend in alterations between histotypes. One par-
ticular region, 8p23.1, showed amplification in clear cell
but deletion in serous tumors. Another region which
showed opposite trend in alteration was 17q12 which har-
bor the oncogene ERBB2; the gene was significantly ampli-
fied in mucinous but deleted in serous tumors. Excluding
borderline cases, 28.6% (4/14) mucinous samples had
amplifications and 15.2% (15/99) of serous tumors had
deletions of ERBB2. 1/5 mucinous borderline also showed
ERBB2 amplification. It should be of note that although
ERBB2 was found significantly deleted in serous tumors,
5/99 (5.1%) of serous samples harbored the amplification,
close to the 3% reported by TCGA for high grade serous
[23]. No ERBB2 deletion was observed in the mucinous
samples. As serous tumors have a comparatively larger
sample size than the other histotypes, we would expect
more significant regions for this histotype. Nevertheless,
using stringent criteria, we were able to identify some sig-
nificant CNA for the lower prevalent tumors.
Figure 1 Overview of copy number aberrations in EOC from 3 datasets from chromosomes 1-X. Chromosomes are shown in alternating
blocks of grey. The centromere for each chromosome is shown as a dotted line. (a) Frequency (%) of occurrence of amplification (red) and
deletion (blue) from chromosome 1 to X in epithelial ovarian cancer from the merged 3 datasets. Major regions of alterations reported in other
studies are similarly observed: e.g. chr 3, 8, 17, and 20. (b) Frequency (%) of occurrence in the 4 main histotypes of EOC. Threshold for frequency
was set at LRR ≥ |0.2|. The frequency for serous tumors is similar to that in (a). However, frequency for the lower prevalent histotypes showed
evident differences, indicating the molecular differences between the histotypes.
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we mapped genes to regions that were identified in each
histotype. 6375 unique genes were found to be altered:
2682 amplifications and 3712 deletions (Additional file 2:
Table S1). 91% of genes were amplified and 97.1% deleted
in serous tumors, 19.1% amplified and 1.5% deleted in
clear cell, 14.3% amplified in endometrioid, and 0.5% amp-
lified and 11.5% deleted in mucinous. A total of 5360
genes were specific to each histotype (amplification=2014,
deletion=3346), 5011 in serous tumors, 193 in endome-
trioid tumors, 79 in clear cell tumors, and 77 in mucinous
tumors. Within each histotype, the type of alterationsvaried. Clear cell tumors had more amplified genes than
deleted genes, while mucinous and serous tumors had
more deleted genes than amplified genes. Only amplified
genes were found in endometrioid tumors. Figure 3 shows
the Venn diagram of overlapping genes in the lower preva-
lent histotypes. Due to the differences in sample size of
each histotype, comparisons between overlapped genes
were limited to genes found only in the non-serous
tumors where the sample sizes are more comparable. A
small number of overlapped amplified and deleted genes
between clear cell and mucinous tumors were observed;
none with endometrioid. This suggests that most of the
Figure 2 Significance of copy number alterations (green) in clear cell, endometrioid, mucinous, and serous histotypes are shown in 4
horizontal tracks respectively. GISTIC q-values (y-axis) are shown as –log10. Regions that passed the statistical selection criteria (see Methods)
are shown as: amplification (red) and deletion (blue). Some known cancer and putative genes are indicated at the bottom of the plots. ERBB2 in
chr17 is shown to be amplified in the mucinous track. Note scale difference in y-axis for the histotypes.
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evidence of molecular differences between histotypes.
Despite larger sample size in serous histotype, comparison
of CNA found in the lower prevalent histotypes with ser-
ous is also of interest (Additional file 3: Figure S2). Clear
cell tumors had the highest number of common altered
genes with serous tumors (7.6%) while endometrioid
tumors had the lowest number of common altered genes;
3.0% common altered genes with serous tumors only.
There is also more overlap on amplifications than
deletions.
Consistency with other studies
Three studies have reported copy number changes in
EOC [16,17,24] (Additional file 4: Table S2). These stud-
ies focused on global changes in EOC rather than
histotype-specific alterations. Nevertheless, histotype-
specific alterations from our study should overlap to
some degree with these reported genes. We compiled alist of 551 significant genes reported in the 3 studies of
which 545 genes were reported by either Haverty et al.
or Gorringe et al. Eleven genes (2%) were commonly
identified in at least 2 of the studies. In comparison,
39.2% (216/551) of genes were found in our study, indi-
cating that our approach can identify copy number
altered genes. We also compared our findings in serous
tumors with TCGA high grade serous study (n=489) [23]
where they reported 63 regions of gains and 50 regions
of deletion. Based on overlapping of genes (if available)
or genomic regions, 29/63 (46%) amplified and 27/50
(54%) deleted regions were also found in our study
(n=101) (Additional file 5: Table S3).
Copy number alterations in known cancer genes
300 cancer genes were previously reported [25], of which
76 cancer genes were found within the altered regions
(Table 1). We found that copy number alterations of
these cancer genes were specific to histotypes as well;
Figure 3 Venn diagram of copy number altered genes between the lower prevalent histotypes. Left: amplified genes; Right: deleted
genes. Clear cell tumors had more amplified genes than deleted genes while mucinous tumors had more deleted genes than amplified genes.
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deletion in mucinous; RB1 deletion in both clear cell
and serous tumors; TP53 and MAP2K4 deletion in mu-
cinous and serous tumors. ERBB2, a gene implicated in
breast and EOC showed significant focal amplification in
mucinous tumors but deletions in serous tumors. Evalu-
ation of ERBB2 expression between mucinous and ser-
ous tumors in the 3 datasets showed the trend of over
expression of ERBB2 in mucinous compared to serous
(Additional file 6: Table S4). The focal amplification of
ERBB2 has been observed in various studies [26-28],
supporting our findings.
Identification of candidate driver genes in EOC histotypes
To identify candidate driver genes that might contribute
to carcinogenesis of EOC, we looked for genes that
showed association between copy number and gene ex-
pression (Methods, Additional file 1: Figure S1). Table 1
summarized the alterations and potential cancer driver
genes (highlighted in bold) based on cytoband. Pathway
analysis of potential driver genes in Table 1 showed top
molecular functions of these genes to be involved with cell
cycle, cellular development, growth and proliferation.
Candidate drivers in known cancer genes
Among 76 identified cancer genes listed in Table 1,
several genes were potential drivers (highlighted in bold)
in EOC in the association analysis. These include: FH,
GMPS, PIK3CA, EIF4A2, ZNF384, and SS18L1 (amplifi-
cations in serous tumors); TET2, FGFR10P, NF1, ERBB2,
and SH3GL1 (deletions in serous tumors) and ERBB2
(amplifications in mucinous tumors). Figure 4 shows the
association between copy number and gene expression
of ERBB2. The correlation was significant for all 3 data-
sets (Dataset1: R=0.80, p=3.47E-09, Dataset2: R=0.74,p=9.44E-6, Dataset3: R=0.79, p=1.14E-6, meta-p=3.90E-
17), suggesting a driver mechanism. Amplification was
observed in mucinous and deletion in serous tumors. An-
other interesting observation was MYC, TP53, KRAS, and
BRCA1, genes reportedly to be commonly mutated in
cancers but did not show significant association between
copy number and gene expression. Similarly, two other
genes reported to be mutated in EOC (PIK3R1 and
STK11) also did not show potential driver mechanism.
Validation of ERBB2 expression
It is not within the scope of this study to validate the
candidate copy number driver genes. As ERBB2 has po-
tential for targeted therapy, we validated the expressions
of ERBB2 via qPCR of 7 samples in Dataset1 that were
found to be amplified or deleted. It should be noted that
no more samples were available in Dataset2 for valid-
ation. Figure 5 shows the scatter plot between gene ex-
pression from microarray and qPCR (measured as fold-
change). Significant correlation was observed (p=0.007)
between microarray and qPCR. Four ERBB2 amplified
samples (1 serous, 1 mucinous, 1 mucinous borderline,
and 1 clear cell) were expressed correspondingly higher
than the 3 serous samples with deleted ERBB2 (p=0.06,
Wilcoxon). All these data support ERBB2 as a copy
number driver gene in EOC.
Discussion
The study reveals genomics diversity in EOC. It is con-
ceivable that some of these alterations are involved in
the tumorigenesis of EOC but the pathogenesis is likely
regulated by aberrations of histotype specific alterations.
By stratifying based on histotypes, we were able to iden-
tify alterations in the lower prevalent clear cell, endome-
trioid, and mucinous samples. An example is ERBB2.
Table 1 Summary of copy number alterations and potential driver cancer genes
Region AMP DEL Cancer genes
C E M S C E M S
1p36.11 D MDS2
1q21.2-1q21.3 A ARNT,TPM3
















13q14.2 D D RB1
15q14-15q15.1 D BUB1B
16q13-16q23.3 D HERPUD1,CBFB,CDH1,MAF
17p11.2-17p13.2 D D USP6,TP53,PER1,GAS7,MAP2K4
17q11.1-17q21.31 D NF1,SUZ12,TAF15,MLLT6,LASP1,RARA,BRCA1







For simplicity, the altered regions are summarized into cytobands in the first column. Second (AMP) and third (DEL) columns indicate the amplification and deletion
respectively for each histotype (C-clear cell, E-endometrioid, M-mucinous, S-serous). The amplification (A) and deletion (D) status for each histotype are indicated in each
cytoband. The last column shows known cancer genes (from Sanger COSMIC database) that are within the altered regions. In total, 76 genes are listed in this table.
Cancer genes which are potential drivers (i.e. significant correlation between gene expression and copy number alterations) are highlighted in bold.
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EOC with mixed results [29,30]. However, when strati-
fied into histotypes, the high prevalence of ERBB2 amp-
lification in mucinous is clearly evident in our results
and other studies [26-28]. In addition, our results sup-
port ERBB2 as a potential copy number driver gene in
EOC. The differences of ERBB2 copy number alterations
amongst the histotypes could be due to the origin of his-
totypes in EOC. Our study demonstrates the importance
of histotype-specific analyses where the differing copy
number landscape amongst the histotypes adds to the
mounting evidence that EOC should not be treated as
one disease.76 cancer genes listed in Table 1 were found to be
copy number altered in EOC. They include ERBB2,
TPM3, BRCA1, BRAF, KRAS, and PIK3CA; some of
which are potential copy number drivers e.g. PIK3CA
and BRAF in serous histotypes. Another interesting ob-
servation was KRAS, a gene reported to be mutated in
mucinous tumors. In our study, KRAS was not found
significantly altered in mucinous tumors where muta-
tions are common. However, KRAS was significantly
amplified in serous tumors where mutations are rare in
high grade tumors. The reciprocal relationship between
KRAS mutation and copy number alterations is also
observed in gastric cancer [11]. The 8q24.21 region
Figure 4 (See legend on next page.)
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Figure 4 Copy number and gene expression of ERBB2 for 3 datasets. From top: dataset1, dataset2, dataset3. Each row shows (left) the
correlation between copy number and gene expression, and (right) boxplot of copy number across histotypes. Significant correlations were
observed between gene expression and copy number alterations, suggesting a potential copy number driver mechanism.
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histotypes other than mucinous. TCGA study also indi-
cates MYC is highly amplified in high grade serous
tumors. This suggests that MYC inhibitors may be ap-
plicable for these histotypes. For cancer genes which
have been reported to have somatic or germline muta-
tions in EOC, 3 were found to harbor copy deletions in
serous histotype: PIK3R1, BRCA1, and STK11. For
BRCA1, our finding was concordant with previous re-
port that BRCA1 locus could be lost via either deletion
or epigenetic silencing other than mutation in sporadic
EOC [31].
A number of the candidate drivers in Table 1 are also
implicated in translocation aberrations, e.g. TPM3,
BCL9, GMPS, ZNF384 and SS18L1. It’s interesting that
these genes were amplified in endometrioid and/or ser-
ous tumors. TPM3 and BCL9 reside in 1q21, a frequent
site for chromosomal rearrangements. TPM3 was specif-
ically amplified in endometrioid tumors and the gene has
been shown to constitute a fusion gene with NTRK1 which
belongs to the group of TRK oncogenes reported for papil-
lary thyroid carcinoma [32]. Interestingly, NTRK1 is also
significantly amplified only in endometrioid tumors andFigure 5 Scatter plot of ERBB2 gene expression and qPCR of 7 sampl
amplified samples (serous, mucinous, mucinous borderline, and clear cell) h
Significant correlation was observed between gene expression and qPCR (pfurther investigation is required to ascertain if this is due
to gene fusion. BCL9 is a novel oncogene in Wnt signaling
pathway, playing a critical role in epithelial-mesenchymal
transition in colon epithelium and adenocarcinomas
[33,34]. Translocation of BCL9 has been reported with
14q32 [35] and the gene was amplified in both endome-
trioid and serous tumors. Translocations for GMPS,
ZNF384, and SS18L1 were also found in leukemia and syn-
ovial sarcomas [36-40] and all were amplified in serous
tumors.
There are several drugs targeting the genes, e.g. for
ERBB2, inhibitors include Trastuzumab, Lapatinib, and
Pertuzumab. Lately, a clinical trial on combination of Per-
tuzumab, Trastuzumb and Docetaxel improved outcome
of patients with HER2 positive metastatic breast cancer
[41]. BRAF mutations are more common in low grade ser-
ous while BRAF amplification is more common in high
grade serous. Our data showed that it is a potential copy
number driver and hence may be targetable by BRAF-
inhibitors in serous tumors. Most BRAF inhibitors target
various mutations and its efficacy on amplified BRAF is
not yet well understood. A study has shown that BRAF
amplified colorectal cancer cells acquired resistance to thees identified to be copy number altered in Dataset1. 4 ERBB2
ad higher expression than the 3 ERBB2 deleted serous samples.
=0.007).
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cantly amplified in serous histotypes and could be a poten-
tial target for PI3K inhibitors. In a study of PI3K inhibitor
on breast and gynecologic malignancies harboring PIK3CA
mutations, patients with the mutations treated with the in-
hibitor showed higher response rate than patients without
the mutations [43].
In combining the 3 datasets, there was concern with
regards to the genetic diversity amongst the Chinese
Japanese, and Caucasian samples. The Hapmap [44] and
Human Genome Diversity projects [45] have showed
that these ethnic groups are different, though Chinese
(CHB) and Japanese (JPT) tend to have high similarity in
population structure. As genetic differences can be eval-
uated via principal component analysis (PCA) [46], we
used PCA to assess the copy number data of the 3
cohorts. No distinct clustering between the groups
(Additional file 7: Figure S3) was observed, suggesting
that in this particular copy number landscape, the gen-
etic effect is not evident and therefore has minimal effect
in the analyses. We also used ANOVA test to assess
~200 housekeeping genes between the 3 datasets; none
of the genes showed significance (Additional file 8: Table
S5). Note that ERBB2 also did not show any significance.
Nevertheless, genetic differences were taken into consid-
eration in the preprocessing protocol. Individual dataset
was normalized with respect to the relevant ethnic group
from Hapmap data, i.e. Dataset1 with JPT, and Dataset2
with CHB. Ethnic-specific common structural poly-
morphism was also filtered out (see Data analysis) to en-
sure the copy number alterations identified in this study
are de novo alterations in tumors.
We recognize that the regions identified could still be
limited by the individual sample size of the histotypes.
The larger number of copy number altered genes in ser-
ous tumors could be attributed to the larger sample size
in this collection. We performed sub-sampling analyses
to ascertain the effects and in addition, to ensure robust-
ness of results, we used stringent criteria to filter the
regions as well as criteria to consider CNA genes if it
were supported by at least 2 dataset (Additional file 1:
Figure S1). The flip side of this filtering was that true
regions of alterations could be filtered out (as shown in
the green area in Figure 1), leading to probably more
false negatives. Nevertheless, we observed that despite
the filtering and limited sample size of some histotypes,
significant regions were still observed in the less preva-
lent histotypes; e.g. the 1p36.33, 2p11.1, 19q13.31, and
20q13.33 amplification and 9q32 deletion in clear cell
tumors (n=29); 1q21.2-3 amplification in endometrioid
tumors (n=20); 17q12 amplification and p24.1 deletion
in mucinous tumors (n=19). Note that endometrioid
tumors were not available in Dataset 2 although the total
number of tumors was comparable with clear cell andmucinous. The concordance criteria of agreement on 2
datasets in the analytical workflow would thus bias the
identification of regions for this histotype. Despite this,
significant alterations were still observed for endome-
troid (e.g. TPM3) and given the stringent criteria; these
are likely high confidence alterations. It should be noted
that the samples were stratified according to the 4 main
histotypes, including some borderline cases. Although
borderline cases are presented clinically as a different
subtype, they were included to simplify the stratification
of histotypes and analyses. The significance of this ap-
proach can be seen in ERBB2, where both mucinous and
mucinous borderline cases harbor amplification and corre-
sponding up regulation of expression as well. This was
similarly observed in other studies [26-28]. To assess if copy
number alterations differ between borderline and non-
borderline tumors and would thus cause bias in our ana-
lyses, we evaluated PCA of these samples (Additional file 9:
Figure S4). No distinct clustering was observed between the
borderline and non-borderline groups.Conclusions
In summary, our study showed genomic diversity in
EOC and highlighted distinct copy number alterations in
histotypes that may have potential for drug targeted
therapy. ERBB2 is significantly amplified in mucinous
tumors and is a candidate copy number driver gene. By
merging multiple datasets of similar platform, we
demonstrated that CNA in the lower prevalent histo-
types could be elucidated, even with limited sample size.Methods
Dataset1
56 archived frozen tumor samples from the Department
of Gynecology & Obstetrics, Kyoto University Graduate
School of Medicine, Japan were profiled on microarray. It
contained 12 clear cell carcinoma, 6 endometrioid adeno-
carcinoma, 2 mucinous adenocarcinoma, 5 mucinous-
borderline tumors, 26 serous adenocarcinoma, and 5
serous-borderline tumors.Dataset2
46 archived frozen tumor samples collected from
Department of Obstetrics and Gynecology, Tri-Service
General Hospital, Taiwan, containing 9 clear cell, 6 mu-
cinous, and 31 serous.Dataset3
GSE19539 consisting of 8 clear cell, 14 endometrioid, 6
mucinous, and 39 serous [15]. Blood normal available in
the dataset was used for normalization in concordance
with the paper.
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Two collections of archived flash frozen ovarian carcinoma
samples were obtained from the Department of Gynecology
& Obstetrics, Kyoto University Graduate School of Medi-
cine, Japan (Dataset1, N= 56) and Department of Obstetrics
and Gynecology, Tri-Service General Hospital, Taiwan
(Dataset2, N=46). All samples were collected with the
donor’s written informed consent. Ethical clearance has
been approved by the Institutional Review Board for both
institutes. All samples were reviewed by at least one path-
ologist from the respective institutes on histopathological
typing and purity of samples. Tumor genomic DNAs were
extracted by using phenol-chloroform extraction method.
Tumor RNAs were extracted by using Qiazol followed by
column clean-up using miRNeasy kit (Qiagen).
Copy number profiling
Affymetrix Genome-Wide Human SNP Arrays 6.0
(Affymetrix, Santa Clara, California) were used for copy
number analysis according to the cytogenetics protocol
from the manufacturer. Data was pre-processed and nor-
malized with Hapmap JPT or CHB for Japan and Taiwan
samples respectively using the Affymetric Genotyping
Console. Copy number segments were obtained from the
circular binary segmentation (CBS) algorithm [47] imple-
mented in R package DNAcopy using default settings.
Gene expression profiling
Affymetrix GeneChip Human Gene 1.0ST Array was
used for gene expression analysis according to the proto-
cols from the manufacturer. Data was pre-processed and
RMA normalized [48] using Affymetrix Gene Expression
Console. Expressions for genes were mean-aggregated
for each gene based on Affymetrix probes annotation.
Note: 3 mucinous samples in Dataset2 and 2 serous
samples in Dataset3 do not have corresponding gene ex-
pression data.
Data repository
The gene expression and copy number datasets are
MIAME compliant and have been submitted to National
Centre for Biotechnology Information’s (NCBI) Gene
Expression Omnibus (GEO) website, series accession num-
ber GSE30311.
Quantitative real time PCR
Total and miRNA was isolated from the ovarian carcin-
oma tissues using the miRNeasy kit (QIAGEN), of which
500ng were used to generate cDNA using the RT2 first
strand kit (QIAGEN). For the qPCR run, 200ng of first
strand cDNA was used per gene analysis. To determine
the expression profile, ERBB2 transcript expression
levels were normalized against the averaged expressionlevels of 5 housekeeping genes (ACTB, B2M, GADPH,
HPRT and RPL13A).
Delta-Ct (ΔCt) and fold-change determination
Ct was determined using the SDS software (version 2.3,
Applied Biosystems). Briefly, Ct values were determined by
setting the baseline between cycle 2 of the run (total run:
40 cycles) and 2 cycles before the start of the first log-
phase amplification. The threshold was set by positioning
the limit to the lower third of the earliest amplification.
ΔCt was calculated by the formulae:
ΔCt ¼ Ct GOIð Þ–Ct HKGð Þ
whereby: Ct (GOI): Ct value of the respective gene of inter-
est (GOI), Ct (HKG): average Ct values of the 5 house-
keeping genes (HKG) used in the assay, Fold-change of
the transcript is determined by the following formula:
Fold change ¼ 2 ΔCtð Þ
Data analysis
To identify significant copy number altered regions, we
used a 2-pronged workflow employing the GISTIC algo-
rithm [18]. GISTIC identifies copy number alterations
based on the frequency as well as the log relative ratio
(LRR) signals to compute the q value (false discovery
rate). Default settings were used in the GISTIC analysis,
and amplification and deletion thresholds were set at 0.2
and −0.2 respectively. Additional file 1: Figure S1 shows
the 2-pronged workflow involving merged and individual
copy number datasets to identify copy number alterations.
Alterations were considered significant if it passed the
following filtering criteria: (i) q < 0.25 (individual dataset),
(ii) q < 0.05 (merged dataset), and (iii) concordance in 2 or
more datasets. The significant regions were than mapped
to genes (hg18 Refseq) by averaging the segments within
each gene. ANOVA test was used to identify histotype-
specific alterations. The analyses resulted in a list of sig-
nificant gain and loss genes for each histotype, summar-
ized in Figure 2 and Table 1 (known cancer genes).
To identify potential driver genes, non-parametric Spear-
man correlation was used to assess association between
gene expression and copy number alterations of individual
gene for each dataset (Additional file 1: Figure S1). Fisher’s
combined probability test (meta-p) [49] was then used to
combine the correlation statistics from each dataset to
identify potential driver genes. This hypothesis driven as-
sociation approach has been used to identify potential can-
cer driver genes [50,51]. Potential driver genes of known
cancer genes are listed in Table 1 (in bold).
PCA plots were generated using Partek Genomics
Suite (Partek, Missouri, USA). Pathway analyses were
performed using Ingenuity Pathway Analysis software
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copy number altered regions in Figure 1 was generated
using the threshold of LRR ≥ |0.2|. All statistical analyses
and plots were done using the R programming package
(http://www.r-project.org).
Sub-sampling analyses to ascertain effects of sample size
To assess the effects of disparate sample size of the his-
totypes in the merged copy number data, multiple sub-
sampling (with replacement) on the merged serous
tumors was performed to ascertain the false positive and
negative. The results showed that ≥97% of genes identi-
fied in sample size of 20–30 were also found in sample
size of 101. However, 43-57% of genes found in the lar-
ger sample size were not identified in the smaller sample
size datasets. In view of this, we have mainly confined
comparison of genes found in the non-serous tumors.
Additional files
Additional file 1: Figure S1. Data Analysis Workflow. Two pronged
approach for individual and merged datasets through selective threshold
of GISTIC q-value and concordance in copy number analysis. As some
histotypes have lower prevalence, filtering thresholds for individual and
merged dataset were set at q<0.25 and q<0.05 respectively to overcome
differences in sample size. In addition, any genomic alterations are
supported by at least 2 datasets (i.e. concordance criteria). Specifically,
the filtering criteria for histotype-specific regions were: (i) q < 0.25
(individual dataset), (ii) q < 0.05 (merged dataset), and (iii) concordance in
2 or more datasets. This resulted in a list of significant gains and loss
regions. To identify copy number driver genes that are specific to
histotype, copy number segments were mapped to genes and ANOVA
was used to identify the differentially altered genes. This resulted in a list
of histotype-specific altered genes. Spearman correlation between gene
expression and copy number was then used to assess potential driver
genes in each individual dataset.
Additional file 2: Table S1. Summary of overlapped amplified and
deleted genes between histotypes.
Additional file 3: Figure S2. Venn diagram of copy number altered
genes between the 4 histotypes. Left: amplified genes; Right: deleted
genes. Clear cell tumors had the highest number of common altered
genes with serous tumors while endometrioid tumors had the lowest
number of common altered genes.
Additional file 4: Table S2. Summary of datasets used for comparison
of commonly altered genes.
Additional file 5: Table S3. Summary of comparison with TCGA.
Additional file 6: Table S4. Comparison of ERBB2 expression between
mucinous and serous tumors.
Additional file 7: Figure S3. Principal component analysis of copy
number altered gene from the merged datasets. The plot shows that there
is minimal copy number alterations difference between the 3 datasets.
Additional file 8: Table S5. Summary of anova results on the 3 datasets.
Additional file 9: Figure S4. Principal component analysis of copy
number altered genes from the merged datasets showing borderline and
non-borderline tumors. Borderline tumors were available only in serous
and mucinous histotypes. No distinct clustering was observed between
borderline and non-borderline tumors for (a) mucinous and (b) serous.
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